-+ 0.00%
-+ 0.00%
-+ 0.00%

Orion Lifts FY25 Outlook on Expectation of Milestone Payment for Prostate Cancer Drug

MT Newswires·12/03/2025 02:54:09
Listen to the news
02:54 AM EST, 12/03/2025 (MT Newswires) -- Orion (ORNAV.HE) raised its outlook for full-year 2025 as it expects to receive a 180 million-euro milestone payment linked to sales of its prostate cancer drug Nubeqa. The Finnish pharmaceutical company now expects net sales to be in the range of 1.82 billion euros to 1.90 billion euros, with an operating profit of between 590 million euros and 670 million euros, according to a Wednesday release. It had previously projected net sales of between 1.64 billion euros and 1.72 billion euros and an operating profit in the 410 million euros to 490 million euros range.